Cargando…

Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel

The first local spread of COVID-19 in Israel was detected in March 2020. Due to the diversity in clinical presentations of COVID-19, diagnosis by RT-PCR alone might miss patients with mild or no symptoms. Serology testing may better evaluate the actual magnitude of the spread of infection in the pop...

Descripción completa

Detalles Bibliográficos
Autores principales: Reicher, Shay, Ratzon, Ronit, Ben-Sahar, Shay, Hermoni-Alon, Sharon, Mossinson, David, Shenhar, Yotam, Friger, Michael, Lustig, Yaniv, Alroy-Preis, Sharon, Anis, Emilia, Sadetzki, Siegal, Kaliner, Ehud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059683/
https://www.ncbi.nlm.nih.gov/pubmed/33884542
http://dx.doi.org/10.1007/s10654-021-00749-1
_version_ 1783681224889335808
author Reicher, Shay
Ratzon, Ronit
Ben-Sahar, Shay
Hermoni-Alon, Sharon
Mossinson, David
Shenhar, Yotam
Friger, Michael
Lustig, Yaniv
Alroy-Preis, Sharon
Anis, Emilia
Sadetzki, Siegal
Kaliner, Ehud
author_facet Reicher, Shay
Ratzon, Ronit
Ben-Sahar, Shay
Hermoni-Alon, Sharon
Mossinson, David
Shenhar, Yotam
Friger, Michael
Lustig, Yaniv
Alroy-Preis, Sharon
Anis, Emilia
Sadetzki, Siegal
Kaliner, Ehud
author_sort Reicher, Shay
collection PubMed
description The first local spread of COVID-19 in Israel was detected in March 2020. Due to the diversity in clinical presentations of COVID-19, diagnosis by RT-PCR alone might miss patients with mild or no symptoms. Serology testing may better evaluate the actual magnitude of the spread of infection in the population. This is the first nationwide seroprevalence study conducted in Israel. It is one of the most widespread to be conducted thus far, and the largest per-country population size. The survey was conducted between June 28 and September 14, 2020 and included 54,357 patients who arrived at the Health Maintenance Organizations to undergo a blood test for any reason. A patient was considered seropositive after two consecutive positive results with two different kits (Abbott and DiaSorin).The overall seroprevalence was 3.8% (95%CI 3.7–4.0), males higher than females [4.9% (95%CI 4.6–5.2) vs. 3.1% (95%CI 2.9–3.3) respectively]. Adolescents had the highest prevalence [7.8% (95%CI 7.0–8.6)] compared to other age groups. Participants who had undergone RT-PCR testing had a tenfold higher risk to be seropositive. The prevalence-to-incidence ratio was 4.5–15.7. Serology testing is an important complimentary tool for assessing the actual magnitude of infection and thus essential for implementing policy measures to control the pandemic. A positive serology test result was recently accepted in Israel as being sufficient to define recovery, with possible far-reaching consequences, such as the deploying of employees to ensure the maintenance of a functional economy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10654-021-00749-1.
format Online
Article
Text
id pubmed-8059683
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-80596832021-04-22 Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel Reicher, Shay Ratzon, Ronit Ben-Sahar, Shay Hermoni-Alon, Sharon Mossinson, David Shenhar, Yotam Friger, Michael Lustig, Yaniv Alroy-Preis, Sharon Anis, Emilia Sadetzki, Siegal Kaliner, Ehud Eur J Epidemiol Covid-19 The first local spread of COVID-19 in Israel was detected in March 2020. Due to the diversity in clinical presentations of COVID-19, diagnosis by RT-PCR alone might miss patients with mild or no symptoms. Serology testing may better evaluate the actual magnitude of the spread of infection in the population. This is the first nationwide seroprevalence study conducted in Israel. It is one of the most widespread to be conducted thus far, and the largest per-country population size. The survey was conducted between June 28 and September 14, 2020 and included 54,357 patients who arrived at the Health Maintenance Organizations to undergo a blood test for any reason. A patient was considered seropositive after two consecutive positive results with two different kits (Abbott and DiaSorin).The overall seroprevalence was 3.8% (95%CI 3.7–4.0), males higher than females [4.9% (95%CI 4.6–5.2) vs. 3.1% (95%CI 2.9–3.3) respectively]. Adolescents had the highest prevalence [7.8% (95%CI 7.0–8.6)] compared to other age groups. Participants who had undergone RT-PCR testing had a tenfold higher risk to be seropositive. The prevalence-to-incidence ratio was 4.5–15.7. Serology testing is an important complimentary tool for assessing the actual magnitude of infection and thus essential for implementing policy measures to control the pandemic. A positive serology test result was recently accepted in Israel as being sufficient to define recovery, with possible far-reaching consequences, such as the deploying of employees to ensure the maintenance of a functional economy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10654-021-00749-1. Springer Netherlands 2021-04-21 2021 /pmc/articles/PMC8059683/ /pubmed/33884542 http://dx.doi.org/10.1007/s10654-021-00749-1 Text en © Springer Nature B.V. 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Covid-19
Reicher, Shay
Ratzon, Ronit
Ben-Sahar, Shay
Hermoni-Alon, Sharon
Mossinson, David
Shenhar, Yotam
Friger, Michael
Lustig, Yaniv
Alroy-Preis, Sharon
Anis, Emilia
Sadetzki, Siegal
Kaliner, Ehud
Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel
title Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel
title_full Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel
title_fullStr Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel
title_full_unstemmed Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel
title_short Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel
title_sort nationwide seroprevalence of antibodies against sars-cov-2 in israel
topic Covid-19
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059683/
https://www.ncbi.nlm.nih.gov/pubmed/33884542
http://dx.doi.org/10.1007/s10654-021-00749-1
work_keys_str_mv AT reichershay nationwideseroprevalenceofantibodiesagainstsarscov2inisrael
AT ratzonronit nationwideseroprevalenceofantibodiesagainstsarscov2inisrael
AT bensaharshay nationwideseroprevalenceofantibodiesagainstsarscov2inisrael
AT hermonialonsharon nationwideseroprevalenceofantibodiesagainstsarscov2inisrael
AT mossinsondavid nationwideseroprevalenceofantibodiesagainstsarscov2inisrael
AT shenharyotam nationwideseroprevalenceofantibodiesagainstsarscov2inisrael
AT frigermichael nationwideseroprevalenceofantibodiesagainstsarscov2inisrael
AT lustigyaniv nationwideseroprevalenceofantibodiesagainstsarscov2inisrael
AT alroypreissharon nationwideseroprevalenceofantibodiesagainstsarscov2inisrael
AT anisemilia nationwideseroprevalenceofantibodiesagainstsarscov2inisrael
AT sadetzkisiegal nationwideseroprevalenceofantibodiesagainstsarscov2inisrael
AT kalinerehud nationwideseroprevalenceofantibodiesagainstsarscov2inisrael